Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Dutasteride can significantly reduce sperm volume, with some users experiencing up to a 90% decrease. While some users report adaptation over time, others suggest switching to finasteride if side effects are too severe.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

Exosomes, cetirizine, melatonin, latanoprost, and caffeine are discussed as potential hair loss treatments. There is skepticism about the effectiveness of exosomes, especially in topical form, but some users report positive results.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

Minoxidil is harmful to pets, especially cats, if they contact it. Users recommend switching to oral minoxidil or taking precautions like washing hands and using head coverings to prevent exposure.

The conversation is about finding a pure high molecular weight hyaluronic acid for the scalp after microneedling. A user suggests using a product from The Ordinary.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Topical finasteride in a liposomal formulation reduces systemic absorption compared to ethanol solutions. The user is seeking sources for such products, noting that popular options like morr-f are not liposomal.

A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.

The user started a hair care routine using 0.5mg finasteride daily, 2ml of 5% minoxidil, and 4.5mg of cetirizine topically to address hair loss. They plan to provide updates and are also interested in cetirizine's potential to reduce scalp itching and redness due to its anti-inflammatory properties.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.

The user reported progress in hair loss treatment using oral finasteride, keto 2% shampoo, and vitamin D. They experienced reduced hair fall, fewer scalp issues, and hope for improved hair density.

Quitting smoking and vaping, along with taking spirulina, improved hair thickness for some users. Others noted that smoking, vaping, and drinking may contribute to hair thinning.